The U.S. Court of Appeals for the Federal Circuit (CAFC) on Thursday upheld the District of Delaware’s grant of judgment as a matter of law (JMOL) that Amgen’s patent claims covering its Repatha cholesterol treatment were invalid for lack of enablement. The court found that Amgen’s composition claims were defined by meeting functional limitations, rather than by structure, and that the patent specifications didn’t enable the preparation of the full scope of the claims without undue experimentation. Judge Lourie authored the opinion. Amgen v. Sanofi (CAFC, Feb. 11, 2020)
Enablement
- CAFC Denies Amgen Petition to Reconsider Enablement Test for Biotech Patents
- Federal Circuit Says Amgen’s Repatha® Patent Claims Require ‘Undue Experimentation’ to Practice
- Implications of Filing Subsequent Patent Applications in the United States (Part III)
- AAM v. Neapco Misreads Federal Circuit Precedent to Create a New Section 101 Enablement-like Legal Requirement – Part II
- New Enablement-Like Requirements for 101 Eligibility: AAM v. Neapco Takes the Case Law Out of Context, and Too Far – Part I
Recent Posts
- Looming Leahy Bill Would End Fintiv Practice at PTAB
- Patent Filings Roundup: Trio of Actions Accuse IP Investments of Coordinated Campaign with Intellectual Ventures Backend; Judge Albright Cancels One of 141 WSOU-Asserted Patents; New Magnetar Entity Surfaces
- International: WIPO Reports Increasing Prevalence of Alternative Dispute Resolution for Business-to-Business Copyright Disputes
- New Tillis-Leahy Bills to Boost Innovation: The Good, the Bad and the Nonsense
- Where Have All of the Ex Parte Appeals Gone?